This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and McKesson (MCK) have performed compared to their sector so far this year.
Here's Why You Should Hold BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Inogen (INGN) Completes Buyout Deal to Expand Product Portfolio
by Zacks Equity Research
Inogen's (INGN) latest acquisition is expected to expand its global Respiratory Care presence and potentially address a large growing bronchiectasis market.
New Strong Buy Stocks for September 19th
by Zacks Equity Research
DHI, DVA, KMTUY, ELAN and BWMX have been added to the Zacks Rank #1 (Strong Buy) List on September 19, 2023.
Three Reasons to Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Stryker's (SYK) New Camera Platform to Improve Surgery Outcomes
by Zacks Equity Research
Stryker's (SYK) latest camera platform is likely to enhance the surgical experience across specialties.
Veeva Systems' (VEEV) New Release to Address Supply-Chain Issues
by Zacks Equity Research
Veeva Systems' (VEEV) new cloud application is likely to improve efficiency and accelerate time-to-market by connecting systems and automating data aggregation, reviews and traceability.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations
by Zacks Equity Research
OPKO Health's (OPK) latest Research Collaboration Agreement is likely to enable it to expand its pipeline to develop orally administered tablet presentations of long-acting peptides.
3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio
by Zacks Equity Research
QuidelOrtho's (QDEL) strong product portfolio raises optimism about the stock.
Surmodics (SRDX) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Investors are optimistic about Surmodics' (SRDX) consistent efforts to boost R&D.
Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) improving non-medical sales and a solid foothold in the broader MedTech space raise optimism about the stock.
Avantor's (AVTR) Tie-Up to Address Temperature-Specific Logistics
by Zacks Equity Research
Avantor's (AVTR) partnership is likely to meet the growing need among biopharma and life science companies for end-to-end solutions.
BD's (BDX) Tie-Up to Explore Flow Cytometry for Clinical Outcomes
by Zacks Equity Research
BD's (BDX) latest partnership is likely to accelerate the delivery of innovative personalized therapies to patients who need them the most.
Align Technology's (ALGN) New Feature to Boost Patient Experience
by Zacks Equity Research
Align Technology's (ALGN) introduction of the new SmartForce feature is expected to minimize the number of attachments while maintaining predictable treatment outcomes.
HealthEquity (HQY) Surpasses Q2 Earnings Estimates, FY24 View Up
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in all its segments, in the second quarter of fiscal 2024.
Why You Should Add Surmodics (SRDX) Stock to Your Portfolio
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Here's Why DaVita HealthCare (DVA) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Retain PacBio (PACB) Stock for Now
by Zacks Equity Research
PacBio's (PACB) product development activities raise optimism about the stock.
Are Medical Stocks Lagging McKesson (MCK) This Year?
by Zacks Equity Research
Here is how McKesson (MCK) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and RadNet
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and RadNet are part of the Zacks Industry Outlook article.
Abbott's (ABT) New Positive Data Favors OCT in Stent Implantation
by Zacks Equity Research
Abbott's (ABT) latest late-breaking data reflects OCT's potential to improve clinical practice related to stent placement.
Masimo's (MASI) Inks Agreement to Improve Patient Outcomes
by Zacks Equity Research
Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.